S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
NASDAQ:BDTX

Black Diamond Therapeutics (BDTX) Stock Price, News & Analysis

$5.26
-0.04 (-0.75%)
(As of 04/19/2024 ET)
Today's Range
$5.17
$5.57
50-Day Range
$3.78
$5.74
52-Week Range
$1.43
$6.85
Volume
386,747 shs
Average Volume
494,751 shs
Market Capitalization
$272.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.25

Black Diamond Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
132.9% Upside
$12.25 Price Target
Short Interest
Healthy
3.94% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.71) to ($1.79) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.83 out of 5 stars

Medical Sector

556th out of 907 stocks

Biological Products, Except Diagnostic Industry

91st out of 149 stocks

BDTX stock logo

About Black Diamond Therapeutics Stock (NASDAQ:BDTX)

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

BDTX Stock Price History

BDTX Stock News Headlines

Now Open: Crypto emergency update
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
Now Open: Crypto emergency update
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
BDTX Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics Inc (BDTX)
Black Diamond Therapeutics Inc.
Solitario: Q3 Earnings Snapshot
Black Diamond Therapeutics Inc Ordinary Shares BDTX
Black Diamond Therapeutics (BDTX) Receives a Buy from Piper Sandler
See More Headlines
Receive BDTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Black Diamond Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/12/2024
Today
4/21/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:BDTX
Web
N/A
Fax
N/A
Employees
54
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.25
High Stock Price Target
$16.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+132.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-82,440,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.26 per share

Miscellaneous

Free Float
47,027,000
Market Cap
$272.05 million
Optionable
Optionable
Beta
2.64
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Mark A. Velleca M.D. (Age 60)
    Ph.D., CEO, President & Chairman
    Comp: $43.89k
  • Dr. David M. Epstein Ph.D. (Age 65)
    Co-Founder & Director
    Comp: $885.08k
  • Dr. Fang Ni Pharm.D. (Age 37)
    CFO, Principal Financial Officer and Chief Business Officer
    Comp: $656.33k
  • Mr. Brent Hatzis-Schoch Esq.Mr. Brent Hatzis-Schoch Esq. (Age 59)
    J.D., COO & General Counsel
    Comp: $683.29k
  • Dr. Elizabeth Buck Ph.D. (Age 49)
    Co-Founder & Chief Scientific Officer
    Comp: $340.47k
  • Ms. Erika Jones (Age 39)
    VP of Finance, Corporate Controller & Principal Accounting Officer
  • Ms. Elizabeth L. Montgomery (Age 52)
    Chief People Officer
  • Dr. Sergey Yurasov M.D. (Age 55)
    Ph.D., Chief Medical Officer
  • Ms. Melanie Morrison
    Chief Development Officer

BDTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Black Diamond Therapeutics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Black Diamond Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BDTX shares.
View BDTX analyst ratings
or view top-rated stocks.

What is Black Diamond Therapeutics' stock price target for 2024?

4 brokers have issued 1-year target prices for Black Diamond Therapeutics' shares. Their BDTX share price targets range from $10.00 to $16.00. On average, they anticipate the company's stock price to reach $12.25 in the next year. This suggests a possible upside of 132.9% from the stock's current price.
View analysts price targets for BDTX
or view top-rated stocks among Wall Street analysts.

How have BDTX shares performed in 2024?

Black Diamond Therapeutics' stock was trading at $2.81 on January 1st, 2024. Since then, BDTX stock has increased by 87.2% and is now trading at $5.26.
View the best growth stocks for 2024 here
.

Are investors shorting Black Diamond Therapeutics?

Black Diamond Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 2,040,000 shares, an increase of 12.7% from the March 15th total of 1,810,000 shares. Based on an average daily trading volume, of 592,500 shares, the days-to-cover ratio is presently 3.4 days.
View Black Diamond Therapeutics' Short Interest
.

When is Black Diamond Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our BDTX earnings forecast
.

How were Black Diamond Therapeutics' earnings last quarter?

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) announced its earnings results on Tuesday, March, 12th. The company reported ($0.34) earnings per share for the quarter, beating analysts' consensus estimates of ($0.47) by $0.13.

What other stocks do shareholders of Black Diamond Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Black Diamond Therapeutics investors own include Alector (ALEC), Alteryx (AYX), Editas Medicine (EDIT), Gossamer Bio (GOSS), Micron Technology (MU), NVIDIA (NVDA), Homology Medicines (FIXX), II-VI (IIVI), Intel (INTC) and Invitae (NVTA).

When did Black Diamond Therapeutics IPO?

Black Diamond Therapeutics (BDTX) raised $151 million in an initial public offering on Thursday, January 30th 2020. The company issued 8,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies and Cowen served as the underwriters for the IPO and Canaccord Genuity was co-manager.

How do I buy shares of Black Diamond Therapeutics?

Shares of BDTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BDTX) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners